Link to full page (citation export, more details):

Three stories on Eph kinase inhibitors: From in silico discovery to in vivo validation

Full Text PDF:

PDF icon Unzue_Lafleur_EJMC2016.pdf

SI PDF:

PDF icon Unzue_Lafleur_EJMC2016_SI.pdf

Authors:
A. Unzue; K. Lafleur; H. Zhao; T. Zhou; J. Dong; P. Kolb; J. Liebl; S. Zahler; A. Caflisch; C. Nevado

Journal: Eur. J. Med. Chem.
Year: 2016
Volume: 112
Pages: 347-366
DOI: 10.1016/j.ejmech.2016.01.057
Type of Publication: Journal Article

Keywords:
Animals; Computer Simulation; Drug Design; Humans; Isoquinolines; Neoplasms; Protein Kinase Inhibitors; Quinoxalines; Receptor, EphB2; Structure-Activity Relationship; Xanthine

Abstract:

Several selective and potent EphB4 inhibitors have been discovered, optimized and biophysically characterized by our groups over the past years. On the outset of these discoveries high throughput docking techniques were applied. Herein, we review the optimization campaigns started from three of these hits (Xan-A1, Pyr-A1 and Qui-A1) with emphasis on their in depth in vitro and in vivo characterization, together with previously unpublished angiogenesis and fluorescence based assays.